{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:23:55Z","timestamp":1767677035784},"reference-count":32,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2001,12,24]],"date-time":"2001-12-24T00:00:00Z","timestamp":1009152000000},"content-version":"vor","delay-in-days":815,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetic Medicine"],"published-print":{"date-parts":[[1999,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p> <jats:bold>Aims<\/jats:bold>\u2003Hepatic glycogen stores have been shown to be depleted, and glucagon stimulated hepatic glucose production reduced, in Type 1 diabetic subjects. Co\u2010administration of amylin and insulin has been shown to replete hepatic glycogen stores in diabetic animal models. The aim of the present study was to investigate the effect of amylin replacement on hepatic glucagon responsiveness in humans.<\/jats:p><jats:p> <jats:bold>Methods<\/jats:bold>\u2003Thirteen Type 1 diabetic men were studied in a double\u2010blind, placebo\u2010controlled, cross\u2010over study after 4\u2003weeks of subcutaneous pramlintide (30\u2003\u03bcg q.i.d.) or placebo administration. Following an overnight fast, plasma glucose was kept above 5\u2003mmol\/l (baseline 210\u2013240\u2003min) with an insulin infusion rate of 0.25\u2003mU.kg<jats:sup>\u20131<\/jats:sup>.min<jats:sup>\u20131<\/jats:sup>. To control portal glucagon levels, somatostatin was infused at a rate of 200\u2003\u03bcg\/h. Basal growth hormone (2\u2003ng.kg<jats:sup>\u20131<\/jats:sup>.min<jats:sup>\u20131<\/jats:sup>) and glucagon (0.7\u2003ng.kg<jats:sup>\u20131<\/jats:sup>.min<jats:sup>\u20131<\/jats:sup>) were replaced. Glucagon infusion was increased to 2.1\u2003ng.kg<jats:sup>\u20131<\/jats:sup>.min<jats:sup>\u20131<\/jats:sup> at 240\u2013360\u2003min (step 1) and to 4.2\u2003ng.kg<jats:sup>\u20131<\/jats:sup>.min<jats:sup>\u20131<\/jats:sup> at 360\u2013420\u2003min (step 2).<\/jats:p><jats:p> <jats:bold>Results<\/jats:bold>\u2003Baseline plasma glucose (5.59\u2003\u00b1\u20030.16 vs. 5.67\u2003\u00b1\u20030.25\u2003mmo\/l) and endogenous glucose production (EGP) (1.32\u2003\u00b1\u20030.22 vs. 1.20 \u00b1 0.13\u2003mg.kg<jats:sup>\u20131<\/jats:sup>. min<jats:sup>\u20131<\/jats:sup>) were similar and the response to glucagon was unaffected by pramlintide (glucose: step 1; 6.01\u2003\u00b1\u20030.31 vs. 5.94\u2003\u00b1\u20030.38\u2003mmo\/l, step 2; 6.00\u2003\u00b1\u20030.37 vs. 5.96\u2003\u00b1\u20030.50\u2003mmol\/l, EGP: step 1; 1.91\u2003\u00b1\u20030.18 vs. 1.83\u2003\u00b1\u20030.15\u2003mg.kg<jats:sup>\u20131<\/jats:sup>.min<jats:sup>\u20131<\/jats:sup>, step 2; 2.08\u2003\u00b1\u20030.17 vs. 1.96\u2003\u00b1\u20030.16\u2003ng.kg<jats:sup>\u20131<\/jats:sup>.min<jats:sup>\u20131<\/jats:sup>, pramlintide vs. placebo). Glucose disposal rates were similar at baseline (2.44\u2003\u00b1\u20030.13 vs. 2.28\u2003\u00b1\u20030.09\u2003mg.kg<jats:sup>\u20131<\/jats:sup>.min<jats:sup>\u20131<\/jats:sup>, pramlintide vs. placebo) as well as during the glucagon challenge (<jats:italic>P<\/jats:italic>\u2010values all\u2003&gt;\u20030.2).<\/jats:p><jats:p> <jats:bold>Conclusions<\/jats:bold>\u2003Co\u2010administration of pramlintide and insulin to Type 1 diabetic subjects for 4\u2003weeks does not change the plasma glucose or endogenous glucose production response to a glucagon challenge, following an overnight fast. In addition, pramlintide administration does not appear to alter insulin\u2010mediated glucose disposal.<\/jats:p>","DOI":"10.1046\/j.1464-5491.1999.00162.x","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T09:49:57Z","timestamp":1027676997000},"page":"861-866","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects"],"prefix":"10.1111","volume":"16","author":[{"given":"L.","family":"\u00d8rskov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Nyholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Yde","family":"Hove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. H.","family":"Gravholt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,24]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117727"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00403290"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90785-2"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(91)80051-4"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.46.4.632"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(99)90232-9"},{"key":"e_1_2_7_8_2","first-page":"A0117","article-title":"The human amylin analogue pramlintide inhibited glucagon secretion in type 1 diabetic subjects","volume":"46","author":"Fineman F","year":"1997","journal-title":"Diabetes"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050646"},{"key":"e_1_2_7_10_2","first-page":"524","article-title":"Role of amylin in diabetes and in regulation of nutrient load","volume":"14","author":"Young A","year":"1998","journal-title":"Nutrition"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050088"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.18.8.1179"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/335632a0"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.40.8.998"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.3.1083"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00400683"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02658511"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00505182"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00403967"},{"key":"e_1_2_7_20_2","unstructured":"Forster CD Taylor JY Macdonald IA.Monitoring molecules in neuroscience: the assay of the catecholamine content of small Volumes of human plasma. Gronningen:University of Gronningen.; 173\u2013175. 1991."},{"key":"e_1_2_7_21_2","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2337\/diab.36.8.914","article-title":"Estimation of endogenous glucose production during hyperinsulinemic\u2013euglycemic glucose clamps","volume":"36","author":"Finegood DT","year":"1987","journal-title":"Diabetes"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1983.55.2.628"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.18.5.715"},{"key":"e_1_2_7_24_2","volume-title":"Clinical Research in Diabetes and Obesity, Part I.\n\t\t\t\t\t\t Methods, Assesment, and Metabolic Regulation.","author":"Cherrington A\u2010D.","year":"1997"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.182.4108.171"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(78)90291-3"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00400639"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(91)81113-M"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.36.3.382"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.31.10.917"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(91)80380-L"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.78.5.1257"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(63)91500-9"}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1464-5491.1999.00162.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1464-5491.1999.00162.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T21:10:25Z","timestamp":1698527425000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1464-5491.1999.00162.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[1999,10]]}},"alternative-id":["10.1046\/j.1464-5491.1999.00162.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1464-5491.1999.00162.x","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,10]]},"assertion":[{"value":"2001-12-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}